Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
1.
Journal of Experimental Hematology ; (6): 855-859, 2019.
Artículo en Chino | WPRIM | ID: wpr-771872

RESUMEN

OBJECTIVE@#To investigate the short-term therapeutic efficacy, survival time and side effects in newly diagnosed multiple myeloma patients treated with TCD regimen consisted of thalidomide, cyclophosphiamide and dexamethasone, and BCD reginen consisted of bortezomib, cyclophsphamide and dexamethasone.@*METHODS@#The clinical data of newly diagnosed MM patients admitted in our hospital from January 2011 to January 2018 were collected and analyzed retrospectively. According to chemotherapectic regimen, 106 patients were divided into 2 groups: 53 cases in one group were treated with TCD regimen (TCD group), and 53 cases in another group were treaded with BCD regimen (BCD group). The therapeutic efficacy, median PFS and OS time and incidence of side effects in 2 groups were compared, at the same time the relationship of the remission degree and the factors in different subgroups with the therapeutic efficacy was analyzed in 2 groups.@*RESULTS@#There was no significant difference in the ≥MR rate between 2 groups (P>0.05). The ≥PR rate, ≥VGPR rate and CR rate of BCD group were significantly higher than TCD group (P<0.05). The median PFS time of patients in BCD group were significantly longer than that in TCD group (P<0.05). There was no significant difference in the median OS time of patients between 2 groups (P<0.05). The median OS time of ≥MR patients in TCD group was significantly longer than that of <MR patients (P<0.05). The median OS time of ≥PR patients in TCD group were significantly longer than that of <PR patients (P<0.05). The median OS time of ≥VGPR patients in BCD group was significantly longer than that of <VGPR patients (P<0.05). There was no significant difference in the median OS time of ≥PR and <PR patients in BCD group (P>0.05). The ORR of ≥VGPR patients in BCD group was significantly higher than that in TCD group (P<0.05). There was no significant difference in the incidence of infection, fatigue, gastrointestinal reactions and bone marrow suppression between 2 groups (P<0.05). The incidence of numbness in distal extremities and herpes zoster in BCD group was significantly higher than that in TCD group (P<0.05).@*CONCLUSION@#TCD and BCD in the treatment of patients with NDMM possess the same disease control effects; BCD regimen application can efficiently improve remission degree and prolong PFS time; but TCD regimen application have the advantages in reducing the side effects risk and improving treatment tolerance.


Asunto(s)
Humanos , Protocolos de Quimioterapia Combinada Antineoplásica , Bortezomib , Supervivencia sin Enfermedad , Mieloma Múltiple , Estudios Retrospectivos , Resultado del Tratamiento
2.
Chinese Journal of Epidemiology ; (12): 499-502, 2004.
Artículo en Chino | WPRIM | ID: wpr-342326

RESUMEN

<p><b>OBJECTIVE</b>To describe the distribution of reduced folate carrier gene (RFC1)genotype and allele frequency between southern and northern, female and male Chinese population.</p><p><b>METHOD</b>RFC1 (A80G) genotype was detected, using polymerase chain reaction-restriction fragment length polymorphism (RFLP-PCR) on 720 blood spot DNA from the normal subjects.</p><p><b>RESULTS</b>The frequencies of the northern population with AA, GG and GA genotypes were 22.28%, 31.09% and 46.63%, and the frequencies of the southern population were 18.56%, 22.75% and 58.68%, respectively. Findings showed that there were significant differences between southerners and northerners in RFC1 (A80G) genotype (P < 0.01). There was no significant difference between G allele frequency of the northern (52.10%) and southern population (54.40%). The frequencies of male with RFC1 (A80G) AA, GG and GA genotype were 24.88%, 25.85% and 49.27%, and among female were 18.83%, 27.77% and 53.40%, respectively. There were no significant differences between male and female in RFC1 genotype (P > 0.05), or between G allele frequency in female (50.49%) and that in male (54.47%).</p><p><b>CONCLUSIONS</b>The distribution of RFC1 genotype seemed to be consistent with neural tube defects (NTDs) while its prevalence among the northerners was higher than that of southerners, with female having a higher NTDs prevalence. This study provided genetic epidemiological data for etiological hypothesis between RFC1 and diseases relative to folate metabolism.</p>


Asunto(s)
Femenino , Humanos , Masculino , Alelos , Proteínas Portadoras , Genética , Fisiología , China , Etnología , Ácido Fólico , Metabolismo , Predisposición Genética a la Enfermedad , Genotipo , Proteínas de la Membrana , Genética , Proteínas de Transporte de Membrana , Metilenotetrahidrofolato Reductasa (NADPH2) , Mutación , Genética , Defectos del Tubo Neural , Genética , Reacción en Cadena de la Polimerasa , Polimorfismo Genético , Genética , Polimorfismo de Longitud del Fragmento de Restricción
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA